SCHEMBL24904347

SCHEMBL24904347

CNC(=O)CN(C)C(=O)c1ccc(C(C)C)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.59
HDAC1 Q13547 3/20 0.59
HPGD P15428 2/20 0.44
FASN P49327 1/20 0.42
USP5 P45974 1/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 1/20 0.39
CYP2C9 P11712 1/20 0.39
F2 P00734 1/20 0.39
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16982007 0.83 RAB9A (0.46) HDAC6HDAC1HPGDFASNUSP5
SCHEMBL23417114 0.82 KMT2A (0.47) TDP1MEN1KMT2ARAB9A
SCHEMBL2565715 0.80 F2 (0.51) HDAC6HDAC1HPGDTDP1MEN1
SCHEMBL10169810 0.78 USP5 (0.47) HDAC6HDAC1HPGDFASNUSP5
SCHEMBL24904346 0.78 HPGD (0.44) HDAC6HDAC1HPGDFASNUSP5
SCHEMBL24904338 0.76 HPGD (0.56) HDAC6HDAC1HPGDFASNUSP5
SCHEMBL13496824 0.76 ACACB (0.46) HDAC6HDAC1HPGDFASNUSP5
SCHEMBL20715645 0.76 HPGD (0.51) HDAC6HDAC1HPGDUSP5MEN1
SCHEMBL24713185 0.76 HPGD (0.55) HDAC6HDAC1HPGDUSP5CYP2C9
SCHEMBL19818808 0.75 HPGD (0.48) HDAC6HDAC1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230018460-A1 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS Infex Therapeutics Limited (GB) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230018460-A1 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS CPN1, CMBL, ALDH7A1 HDAC6 1508/4885HDAC1 953/4885HPGD 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.